Company intelligence / Profile preview

KQ-2003

Ownership: Private
Development stage: Other

Overview

K-Quat is a biotechnology company focused on the development of novel small molecule therapeutics targeting potassium channels for the treatment of neurological disorders. The company's lead program, KQ-2003, is a potassium channel opener designed to address unmet needs in epilepsy and neuropathic pain. By modulating neuronal excitability, K-Quat aims to provide more effective and better-tolerated treatment options for patients suffering from hyperexcitability-related conditions. The company is currently advancing its pipeline through pre-clinical development stages.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on KQ-2003.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KQ-2003.

Explore the full profile